Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia

Cancer

Volumn 117, Issue 10, 2011, Pages 2163-2169

  Weiss, Lukas ^a   Melchardt, Thomas ^a   Egle, Alexander ^a   Grabmer, Christoph ^b   Greil, Richard ^a   Tinhofer, Inge ^a,c  

^a University Hospital Salzburg   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

chronic lymphocytic leukemia; prognosis; regulatory T cells; tumor immune evasion

Indexed keywords

CD38 ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER THERAPY; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; EARLY CANCER; FEMALE; GENE MUTATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; TREATMENT INDICATION; TUMOR IMMUNITY;

CD4-POSITIVE T-LYMPHOCYTES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; PROGNOSIS; RISK; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 79955500329     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25752     Document Type: Article

References (33)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS., Clinical staging of chronic lymphocytic leukemia. Blood. 1975; 46: 219-234.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK., Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94: 1848-1854. (Pubitemid 29430400)
4. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1910-1916. (Pubitemid 32064784)
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94: 1840-1847. (Pubitemid 29430399)
6. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351: 893-901. (Pubitemid 39096916)
7. Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood. 2006; 108: 2950-2956.
8. Tinhofer I, Weiss L, Gassner F, Rubenzer G, Holler C, Greil R., Difference in the relative distribution of CD4(+) T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes implication for the course of disease. J Immunother. 2009; 32: 302-309.
9. Beyer M, Schultze JL., Regulatory T cells in cancer. Blood. 2006; 108: 804-811. (Pubitemid 44154611)
10. Hiraoka N, Onozato K, Kosuge T, Hirohashi S., Prevalence of FOXP3(+) regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12: 5423-5434. (Pubitemid 44497257)
11. Perez SA, Karamouzis MV, Skarlos DV, et al. CD4(+) CD25(+) regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007; 13: 2714-2721. (Pubitemid 46788040)
12. Curiel TJ, Coukos G, Zou LH, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10: 942-949. (Pubitemid 39273735)
13. Lyons AB., Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000; 243: 147-154.
14. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998; 102: 1515-1525. (Pubitemid 28492218)
15. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002; 100: 1177-1184. (Pubitemid 34864269)
16. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203: 1693-1700. (Pubitemid 44036275)
17. Liu WH, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4(+) T reg cells. J Exp Med. 2006; 203: 1701-1711. (Pubitemid 44036276)
18. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood. 2002; 99: 4087-4093. (Pubitemid 35332051)
19. Beyer M, Kochanek M, Darabi K, et al. Reduced frequencies and suppressive function of CD4(+)CD25(hi) regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005; 106: 2018-2025. (Pubitemid 41291715)
20. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep. 2008; 20: 677-682.
21. Fu JL, Xu DP, Liu ZW, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007; 132: 2328-2339.
22. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005; 11: 8326-8331. (Pubitemid 41746944)
23. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC., Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010; 24: 512-520.
24. Peng LM, Kjaergaard J, Plautz GE, et al. Tumor-induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol. 2002; 169: 4811-4821. (Pubitemid 35217144)
25. Jak M, Mous R, Remmerswaal EBM, et al. Enhanced formation and survival of regulatory T cells in CLL. Blood. 2008; 112: 390.
26. Ranheim EA, Cantwell MJ, Kipps TJ., Expression of Cd27 and its ligand, Cd70, on chronic lymphocytic leukemia B-cells. Blood. 1995; 85: 3556-3565.
27. von Boehmer H., Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005; 6: 338-344. (Pubitemid 41716770)
28. Knutson KL, Dang YH, Lu HL, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006; 177: 84-91. (Pubitemid 43939119)
29. Coenen JJA, Koenen HJPM, van Rijssen E, Hilbrands LB, Joosten I., Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27(+) subset of human CD4(+) CD25(+) regulatory T cells. Blood. 2006; 107: 1018-1023. (Pubitemid 43156300)
30. Giannopoulos K, Schmitt M, Wlasiuk P, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia. 2008; 22: 222-224.
31. Colombo MP, Piconese S., Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer. 2007; 7: 880-887. (Pubitemid 350006256)
32. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad U S A. 2002; 99: 6955-6960. (Pubitemid 34526239)
33. Yan XJ, Albesiano E, Zanesi N, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006; 103: 11713-11718. (Pubitemid 44182516)